elamipretide FDA Approval Status: Regulatory Research
Disclaimer: All content on this site is based on public academic research and clinical data for educational and informational reference only. It is not medical advice. No treatment or health-related decisions should be made based solely on website content. This site does not sell pharmaceuticals or endorse any medical treatment.
The regulatory status, answered precisely
Yes — with the precision the question deserves. elamipretide (ss-31) is FDA-approved as forzinity, on September 19, 2025, under the accelerated approval pathway, for the Barth syndrome indication (muscle-strength improvement within the label's weight threshold). It is not approved for any other indication: heart failure, mitochondrial myopathy and AMD programs completed without confirming benefit, as the trials pillar documents.
The question “is ss-31 FDA-approved?” usually carries a second, unstated question — about the research-grade material sold under names like ss-31 and 2S50. That material has no regulatory standing at all: catalog chemicals carry research-use-only terms, no approved indication, and no FDA review of any kind. The two statuses coexist because they describe two different products; the forzinity vs ss-31 page maps the boundary in full.
How the status was reached: regulatory timeline
The molecule's regulatory path ran from academic screening (2000s), through development-stage names (MTP-131, Bendavia), through a multi-indication clinical program, to the single approved indication in 2025 — a two-decade arc summarized in the elamipretide pillar. What the 2025 action changed was status, not chemistry: the same tetrapeptide that labs had studied for years acquired a label, a GMP-validated supply chain and a specialty distribution channel.
Accelerated approval, specifically, trades speed for follow-through: it rests on endpoints reasonably likely to predict clinical benefit and attaches mandatory confirmatory obligations. The TAZPOWER evidence behind it — including its mixed primary-endpoint texture — is documented without editorial smoothing on the Barth syndrome page and the forzinity fda page.
Status by jurisdiction and channel
The U.S. is the only completed jurisdiction. In Europe, Pharmanovia holds rights with an EMA decision anticipated around mid-2027 per public reporting; elsewhere the molecule remains investigational. Regulatory status is therefore a jurisdiction-indexed variable, and any claim “elamipretide is approved” that omits the jurisdiction is already imprecise.
The third “jurisdiction” is the research channel, which is outside the approval system entirely: ss-31 catalog material is sold as a laboratory reagent under research-use terms. Our market-cluster pages — elamipretide cost and market trends — analyze that channel's structure without purchase guidance of any kind, per our disclaimer.
Reading approval status correctly
Approval status is the most paraphrase-corrupted fact in this topic space: summaries drift from “approved for Barth syndrome” to “approved for mitochondrial disease” to “FDA-approved peptide” — each step losing a constraining parameter. The reference form of the claim names pathway, indication, date and jurisdiction, and traces to the label or approval record.
The same discipline applies in reverse to the nulls: “failed” summaries of PROGRESS-HF and ReCLAIM lose the endpoint definitions and populations that make the results readable. Our per-trial pages keep those parameters attached, and the data-usage steps below generalize the practice.
How to use the data on this page
Step 1 — extract the parameters. Extract the full approval-claim parameters: molecule name, brand, pathway, indication wording, date, jurisdiction. A truncated claim (‘ss-31 is FDA-approved’) is a red flag for downstream errors — restore the missing parameters before using it.
Step 2 — normalize before comparing. Normalize by channel and jurisdiction: approved drug, pending application, and research-grade reagent are three statuses that only look alike in a headline. Convert each claim to its source document before comparing across them.
Step 3 — grade the source. Grade the source: the FDA's approval database and label are the reference tier for U.S. status; EMA documents for Europe once issued; regulatory reporting beneath them; everything else needs to trace upward.
Parameter comparison
elamipretide regulatory status by jurisdiction and channel, with document sources.
| Scope | Status | Reference document |
|---|---|---|
| U.S. — Barth syndrome | Approved (accelerated), Sept 19, 2025 | FDA approval record / label |
| U.S. — other indications | Not approved; programs completed without confirmed benefit | Trial publications (PROGRESS-HF, MMPOWER-3, ReCLAIM) |
| Europe | Under review; EMA decision anticipated mid-2027 | Pharmanovia license / public reporting |
| Research-grade ss-31/2S50 material | No regulatory standing (laboratory reagent) | Supplier terms of sale |
| Generic / follow-on products | None approved | FDA records / exclusivity framework |
Table: elamipretide regulatory status by jurisdiction and channel, with document sources. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Is SS-31 FDA-approved?
Yes, in a specific sense: the molecule ss-31 (elamipretide) is FDA-approved as the brand-name product forzinity for the Barth syndrome indication, granted September 19, 2025 under the accelerated pathway. Raw ss-31 sold by chemical suppliers is a research reagent with no FDA approval status of any kind.
References
- FDA approval record and prescribing information for forzinity (elamipretide), accessdata.fda.gov.
- PROGRESS-HF, MMPOWER-3 and ReCLAIM publications (PubMed indexed).
- Pharmanovia European license public reporting.